Dispensing of attention-deficit hyperactivity disorder medications for adults in Aotearoa New Zealand
New Zealand Medical Journal · 2024
DOI: 10.26635/6965.6392 ↗Kurz gefasst
Fachartikel in der Zeitschrift New Zealand Medical Journal, 2024. Verfasst von Ben Beaglehole und 2 weiteren Autor:innen. Beteiligte Einrichtung: Senior Lecturer, Department of Psychological Medicine, University of Otago, Christchurch. Hauptthemen laut MEDLINE: Atomoxetine Hydrochloride, Methylphenidate, Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants.
Abstract (Originalsprache)
aim: To report dispensing trends for attention-deficit hyperactivity disorder (ADHD) in Aotearoa New Zealand, focussing on adults in order to highlight increasing demand for ADHD treatment by adults and to prompt discussion. method: Demographic and dispensing data for ADHD were obtained from the Pharmaceutical Collection between the years 2006 and 2022. This was stratified according to child (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Senior Lecturer, Department of Psychological Medicine, University of Otago, Christchurch.
- Psychiatric Registrar, Te Whatu Ora - Waitaha Canterbury.
- Biostatistician, Department of Psychological Medicine, University of Otago, Christchurch.
Zitieren
APA
Beaglehole, B., Jarman, S., & Frampton, C. (2024). Dispensing of attention-deficit hyperactivity disorder medications for adults in Aotearoa New Zealand. New Zealand Medical Journal. https://doi.org/10.26635/6965.6392
Vancouver
Beaglehole B, Jarman S, Frampton C. Dispensing of attention-deficit hyperactivity disorder medications for adults in Aotearoa New Zealand. New Zealand Medical Journal. 2024. doi:10.26635/6965.6392
BibTeX
@article{Beaglehole2024,
author = {Beaglehole, Ben and Jarman, Stephen and Frampton, Chris},
title = {Dispensing of attention-deficit hyperactivity disorder medications for adults in Aotearoa New Zealand},
journal = {New Zealand Medical Journal},
year = {2024},
doi = {10.26635/6965.6392}
}
EUVIMED